Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 10770.0
(0.19%)
KRW 10770.0
(0.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.52 Billion KRW | -17.28% |
| 2022 | 9.09 Billion KRW | -52.04% |
| 2021 | 18.95 Billion KRW | -54.21% |
| 2020 | 41.4 Billion KRW | 154.34% |
| 2019 | 16.27 Billion KRW | 20.08% |
| 2018 | 13.55 Billion KRW | -27.27% |
| 2017 | 18.64 Billion KRW | -47.04% |
| 2016 | 35.19 Billion KRW | 86.82% |
| 2015 | 18.84 Billion KRW | 89.45% |
| 2014 | 9.94 Billion KRW | 14.04% |
| 2013 | 8.72 Billion KRW | -33.75% |
| 2012 | 13.16 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 45.16 Billion KRW | 517.07% |
| 2024 Q1 | 7.31 Billion KRW | -2.67% |
| 2023 Q4 | 7.52 Billion KRW | 0.59% |
| 2023 FY | 7.52 Billion KRW | -17.28% |
| 2023 Q1 | 8.62 Billion KRW | -5.17% |
| 2023 Q2 | 6.9 Billion KRW | -19.87% |
| 2023 Q3 | 7.47 Billion KRW | 8.22% |
| 2022 Q4 | 9.09 Billion KRW | -11.1% |
| 2022 Q1 | 10.76 Billion KRW | -43.23% |
| 2022 Q2 | 10.48 Billion KRW | -2.6% |
| 2022 Q3 | 10.22 Billion KRW | -2.44% |
| 2022 FY | 9.09 Billion KRW | -52.04% |
| 2021 Q3 | 24.58 Billion KRW | -44.1% |
| 2021 FY | 18.95 Billion KRW | -54.21% |
| 2021 Q1 | 43.11 Billion KRW | 4.12% |
| 2021 Q2 | 43.98 Billion KRW | 2.02% |
| 2021 Q4 | 18.95 Billion KRW | -22.89% |
| 2020 Q4 | 41.4 Billion KRW | 9.09% |
| 2020 FY | 41.4 Billion KRW | 154.34% |
| 2020 Q2 | 10.96 Billion KRW | 37.05% |
| 2020 Q1 | 8 Billion KRW | -51.4% |
| 2020 Q3 | 37.95 Billion KRW | 246.12% |
| 2019 Q3 | 17.35 Billion KRW | -14.4% |
| 2019 FY | 16.27 Billion KRW | 20.08% |
| 2019 Q4 | 16.46 Billion KRW | -5.16% |
| 2019 Q2 | 20.27 Billion KRW | -2.62% |
| 2019 Q1 | 20.82 Billion KRW | 53.99% |
| 2018 Q1 | 19.06 Billion KRW | 3.17% |
| 2018 FY | 13.55 Billion KRW | -27.27% |
| 2018 Q4 | 13.52 Billion KRW | -8.62% |
| 2018 Q3 | 14.8 Billion KRW | -27.01% |
| 2018 Q2 | 20.27 Billion KRW | 6.35% |
| 2017 Q4 | 18.48 Billion KRW | -19.92% |
| 2017 FY | 18.64 Billion KRW | -47.04% |
| 2017 Q1 | 32.84 Billion KRW | -6.6% |
| 2017 Q2 | 26.85 Billion KRW | -18.23% |
| 2017 Q3 | 23.07 Billion KRW | -14.08% |
| 2016 FY | 35.19 Billion KRW | 86.82% |
| 2016 Q2 | 21.51 Billion KRW | -1.13% |
| 2016 Q3 | 31.43 Billion KRW | 46.11% |
| 2016 Q4 | 35.16 Billion KRW | 11.85% |
| 2016 Q1 | 21.76 Billion KRW | 15.71% |
| 2015 Q3 | 10.97 Billion KRW | 1.98% |
| 2015 Q4 | 18.8 Billion KRW | 71.38% |
| 2015 Q2 | 10.76 Billion KRW | -26.38% |
| 2015 Q1 | 14.61 Billion KRW | 46.98% |
| 2015 FY | 18.84 Billion KRW | 89.45% |
| 2014 Q2 | 8.34 Billion KRW | -17.1% |
| 2014 Q3 | 10.07 Billion KRW | 20.71% |
| 2014 Q1 | 10.06 Billion KRW | 15.41% |
| 2014 Q4 | 9.94 Billion KRW | -1.26% |
| 2014 FY | 9.94 Billion KRW | 14.04% |
| 2013 FY | 8.72 Billion KRW | -33.75% |
| 2013 Q1 | 12.82 Billion KRW | -2.61% |
| 2013 Q2 | 10.5 Billion KRW | -18.1% |
| 2013 Q4 | 8.72 Billion KRW | -9.44% |
| 2013 Q3 | 9.63 Billion KRW | -8.28% |
| 2012 FY | 13.16 Billion KRW | 0.0% |
| 2012 Q4 | 13.16 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 109.56 Billion KRW | 93.136% |
| ST Pharm Co.,Ltd. | 299.92 Billion KRW | 97.492% |
| ABL Bio Inc. | 86.06 Billion KRW | 91.262% |
| Cellid, Co., Ltd. | 23.42 Billion KRW | 67.897% |